ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1691

Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns

Francesca Dall'Ara1, Laura Andreoli2, Federica Migliorati3, Giuseppe Armentaro3, Micaela Fredi4, Micol Frassi5, Mara Taraborelli3, Franco Franceschini4, Stefano Calza6 and Angela Tincani3, 1Department of Clinical and Experimental Sciences,Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, 2Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 3Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, 4Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, 5Spedali Civili of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, 6Unit of Biostatistics and Biomathematics & Unit of Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: remission and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by a fluctuating course. To achieve sustained remission is the ultimate goal of maintenance treatment. However the definition of remission is difficult in SLE. In 2014, an international Task Force named DORIS proposed four definitions of remission. The aim of this study was to evaluate the performance of the DORIS algorithm, to identify the frequency of remission as determined by DORIS for each clinical disease pattern, and to evaluate the impact of remission on damage accrual.

Methods: Monocentric retrospective study. Among all SLE patients followed at the Lupus Clinic between 2014 and 2017, we enrolled patients fulfilling the SLICC 2012 criteria who were visited at least once in 2017 and who had at least 5 biannual medical examinations in the previous 2 years. Definitions of remission according to DORIS and disease patterns are reported in Table 1. Damage accrual was measured by the SDI score1.

Results: 101 SLE patients were enrolled for this study (94% female, mean age 45 years). 505 time-points were evaluated: 211 (42%) were defined as “remission” according to DORIS and in particular 181 (85.5%) were “remission on treatment”. 17.8% of patients were in remission in all the 5 time-points, vice versa 29.7% of patients never got into remission. 17.8% of patients have been in remission for 24 months, while 21.8% of patients less than 6 months. Mean duration of DORIS remission was 7.96 months. The most frequent disease patterns were RR (41,6%) and CQ (41,6%), while CA pattern was present in 16,8% of patients. DORIS remission was most frequently achieved in CQ pattern (65.2% of visits), less frequently in CA (5.9%). At the end of follow-up 50% of patients had a SDI≥1, and cumulative dosage of steroids was significantly associated to damage accrual (p:0.04 OR: 1.04 CI: 1.001-1.088). Moreover patients with at least one time-point in remission according to DORIS had a significantly lower damage accrual (p: 0.01) when compared to patients who never got into remission.

Conclusion: The DORIS algorithm is easy to be employed in clinical practice. In this cohort 30% of patients never achieved remission. Since damage accrual was associated with both cumulative dosage of steroids and unremitted disease, the goal in SLE management should be sustained remission with the lowest dose of steroids.

1)Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–369.

Table 1: Definition of Remission according to DORIS; Definition of disease pattern. PGA: Physician Global Assessment; cSLEDAI: clinical SLEDAI (without anti-dsDNA and C3/C4 levels)

Definition of Remission

Clinical Items

Treatment

cSLEDAI

PGA

Daily dose of prednisone

Antimalarials

Immunosuppressants/

Biologics

Remission “off treatment”

= 0

< 0.5

0

yes

no

Remission “on treatment”

= 0

< 0.5

≤ 5 mg

yes

yes

No Remission

≠0

≥0.5

>5 mg

yes

yes

Definition of disease patterns

Chronic active (CA)

Persistent disease activity over time with a cSLEDAI ≥1 in each visit for at least one year

Relapsing-remitting (RR)

Characterised by periods of disease activity with cSLEDAI ≥1 interspersed with periods of disease inactivity with cSLEDAI = 0 in different visits for at least one year

Clinically quiescent (CQ)

Defined as absence of disease activity with a cSLEDAI = 0 for at least one year


Disclosure: F. Dall'Ara, None; L. Andreoli, None; F. Migliorati, None; G. Armentaro, None; M. Fredi, None; M. Frassi, None; M. Taraborelli, None; F. Franceschini, None; S. Calza, None; A. Tincani, Bristol-Myers Squibb, 2,UCB, Inc., 5.

To cite this abstract in AMA style:

Dall'Ara F, Andreoli L, Migliorati F, Armentaro G, Fredi M, Frassi M, Taraborelli M, Franceschini F, Calza S, Tincani A. Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/application-of-the-doris-algorithm-for-the-definition-of-disease-remission-and-its-relation-with-damage-accrual-over-a-2-year-period-in-a-cohort-of-italian-patients-with-systemic-lupus-erythematosus-c/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/application-of-the-doris-algorithm-for-the-definition-of-disease-remission-and-its-relation-with-damage-accrual-over-a-2-year-period-in-a-cohort-of-italian-patients-with-systemic-lupus-erythematosus-c/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology